283 related articles for article (PubMed ID: 23019410)
21. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
22. Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors?
Sawyer JR; Husain M; Al-Mefty O
Neurosurg Focus; 2001 Mar; 10(3):E6. PubMed ID: 16734409
[TBL] [Abstract][Full Text] [Related]
23. Clival chordomas: considerations after 16 years of endoscopic endonasal surgery.
Zoli M; Milanese L; Bonfatti R; Faustini-Fustini M; Marucci G; Tallini G; Zenesini C; Sturiale C; Frank G; Pasquini E; Mazzatenta D
J Neurosurg; 2018 Feb; 128(2):329-338. PubMed ID: 28409727
[TBL] [Abstract][Full Text] [Related]
24. Surgical Resection and Adjuvant Radiation Therapy in the Treatment of Skull Base Chordomas.
Sanusi O; Arnaout O; Rahme RJ; Horbinski C; Chandler JP
World Neurosurg; 2018 Jul; 115():e13-e21. PubMed ID: 29545225
[TBL] [Abstract][Full Text] [Related]
25. DNA methylation, combined with RNA sequencing, provide novel insight into molecular classification of chordomas and their microenvironment.
Baluszek S; Kober P; Rusetska N; Wągrodzki M; Mandat T; Kunicki J; Bujko M
Acta Neuropathol Commun; 2023 Jul; 11(1):113. PubMed ID: 37434245
[TBL] [Abstract][Full Text] [Related]
26. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.
Gill CM; Fowkes M; Shrivastava RK
Neurosurgery; 2020 Feb; 86(2):E118-E123. PubMed ID: 31504814
[TBL] [Abstract][Full Text] [Related]
27. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis.
Bavi P; Jehan Z; Atizado V; Al-Dossari H; Al-Dayel F; Tulbah A; Amr SS; Sheikh SS; Ezzat A; El-Solh H; Uddin S; Al-Kuraya K
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1708-18. PubMed ID: 16985034
[TBL] [Abstract][Full Text] [Related]
28. Fhit loss-associated initiation and progression of neoplasia in vitro.
Karras JR; Schrock MS; Batar B; Zhang J; La Perle K; Druck T; Huebner K
Cancer Sci; 2016 Nov; 107(11):1590-1598. PubMed ID: 27513973
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.
Horbinski C; Oakley GJ; Cieply K; Mantha GS; Nikiforova MN; Dacic S; Seethala RR
Arch Pathol Lab Med; 2010 Aug; 134(8):1170-6. PubMed ID: 20670138
[TBL] [Abstract][Full Text] [Related]
30. The Significance of Intraoperative Magnetic Resonance Imaging in Resection of Skull Base Chordomas.
Metwali H; Samii A; Gerganov V; Giordano M; Fahlbusch R; Samii M
World Neurosurg; 2019 Aug; 128():e185-e194. PubMed ID: 31003024
[TBL] [Abstract][Full Text] [Related]
31. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.
Longoni M; Orzan F; Stroppi M; Boari N; Mortini P; Riva P
Neuro Oncol; 2008 Feb; 10(1):52-60. PubMed ID: 18094369
[TBL] [Abstract][Full Text] [Related]
33. The brachyury Gly177Asp SNP is not associated with a risk of skull base chordoma in the Chinese population.
Wu Z; Wang K; Wang L; Feng J; Hao S; Tian K; Zhang L; Jia G; Wan H; Zhang J
Int J Mol Sci; 2013 Oct; 14(11):21258-65. PubMed ID: 24232574
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
35. Recurrent loss of chromosome 22 and SMARCB1 deletion in extra-axial chordoma: A clinicopathological and molecular analysis.
Wen X; Cimera R; Aryeequaye R; Abhinta M; Athanasian E; Healey J; Fabbri N; Boland P; Zhang Y; Hameed M
Genes Chromosomes Cancer; 2021 Dec; 60(12):796-807. PubMed ID: 34392582
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
[TBL] [Abstract][Full Text] [Related]
37. Analysis of radiological features relative to histopathology in 42 skull-base chordomas and chondrosarcomas.
Pamir MN; Ozduman K
Eur J Radiol; 2006 Jun; 58(3):461-70. PubMed ID: 16631334
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis of the fragile histidine triad (FHIT) tumor suppressor gene in vesical tumors of cattle with chronic enzootic hematuria (CEH).
Guidi E; Uboldi C; Ferretti L
Cytogenet Genome Res; 2008; 120(1-2):173-7. PubMed ID: 18467844
[TBL] [Abstract][Full Text] [Related]
39. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
40. Decreased fragile histidine triad gene protein expression is associated with worse prognosis in oral squamous carcinoma.
Guerin LA; Hoffman HT; Zimmerman MB; Robinson RA
Arch Pathol Lab Med; 2006 Feb; 130(2):158-64. PubMed ID: 16454554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
